MediWound Files Annual Report on Form 20-F

MediWound Ltd. (Nasdaq: MDWD), a pioneering biotechnology company specializing in next-generation enzymatic therapeutics for tissue repair, has filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. Securities and Exchange Commission (SEC). Announced on March 5, 2026, this filing is accessible through the SEC's website and the company’s investor relations platform.

MediWound is recognized for its innovative approach in wound care. Its flagship product, NexoBrid®, is FDA-approved for the enzymatic removal of eschar in thermal burns, and it is currently marketed in major markets including the United States, European Union, and Japan. This biologic therapy underscores MediWound’s commitment to advancing non-surgical treatment options in the healthcare sector.

Additionally, the company is focused on its late-stage pipeline product, EscharEx®, which is aimed at providing a solution for chronic wound debridement. EscharEx® holds the potential to establish itself as a new standard of care in wound management, reflecting MediWound’s ongoing efforts to address unmet medical needs in this area.

Shareholders interested in receiving a hard copy of the Form 20-F, including audited financial statements, can do so free of charge by contacting the company directly via email or postal service. MediWound encourages engagement with its stakeholders and provides various channels for inquiries. For more information about the company, its product offerings, and ongoing developments, interested parties can visit their official website or follow them on social media platforms.

For any further questions or communications, shareholder contacts are provided for ease of access. MediWound continues to position itself as a leader in biotechnology, committed to enhancing the landscape of healing modalities in tissue repair.

As of the fiscal year ended December 31, 2025, MediWound Ltd. presents a compelling investment opportunity based on its recent filings and growth trajectory. The company's filing of its Form 20-F signals transparency and regulatory compliance, which are critical factors for potential investors.

MediWound continues to establish itself as a key player in the biotechnology sector, particularly in enzymatic therapeutics for tissue repair with its FDA-approved product, NexoBrid®. This biologic’s success in the treatment of thermal burns not only showcases the company’s innovation but also highlights a robust markets presence across the U.S., EU, and Japan. Importantly, NexoBrid presents a relatively stable revenue stream, which is crucial for a biotechnology firm often subject to volatility due to R&D investments.

Investors should also pay attention to the late-stage product EscharEx®, aimed at chronic wound debridement. The product’s investigational status suggests it could redefine existing wound management protocols, presenting a strategic growth avenue. Should EscharEx® receive favorable regulatory outcomes, it could significantly impact revenue growth and market presence, establishing MediWound as a dominant entity in this specialized field.

While the company shows promise, potential investors must remain aware of the inherent risks associated with biotechnology investments. The sector is characterized by high research costs, lengthy regulatory processes, and competitive pressures. It would be prudent for investors to monitor upcoming quarterly releases closely, along with updates on EscharEx®'s clinical trial results, as these will provide insights into the firm's future performance and market viability.

In conclusion, MediWound Ltd. exhibits strong potential for growth, particularly with its pipeline products. For those willing to adopt a long-term investment strategy, this company may offer high rewards commensurate with the risks inherent in the biotechnology sector.